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Editorial on the Research Topic
The Role of Myeloid-Derived Cells in the Progression of Liver Disease
The liver is strategically positioned to drain the intra-abdominal organs through the portal vein.
As such, the liver is constantly challenged with foreign food antigens, bacterial products that
require a high degree of tolerance and restraint. In chronic liver disease, when hepatocyte damage
occurs, this tolerant state is often lost resulting in local and systemic inflammation and fibrosis
development, which may be detrimental to the host. It is well-established that macrophages, as
highly diverse immune cells, play a central role in both the initiation as well as restoration of
inflammation and fibrogenesis. Macrophages can be either embryonically seeded in organs where
they are maintained through self-renewal (1) or derived from infiltrating bone marrow monocyte
precursors (2, 3). Regardless of their origin, they adapt tomicroenvironmental cues within the niche
they reside in and become imprinted with a unique transcriptional signature (4, 5). Technologies
such as single-cell RNA sequencing accelerated discoveries in the field by uncovering the diversity
of monocyte/macrophage functions even during steady-state conditions (6). Nevertheless, our
understanding of the molecular mechanisms that goes astray during disease states, resulting in
the loss of macrophages’ ability to maintain homeostatic functions, remains incomplete. In this
special Research Topic, experts in the field dissect the landscape of myeloid derived cells as well
as neutrophils during chronic liver diseases. Understanding how myeloid cells contribute to injury
and repair will enable the design of new therapies.
INNATE IMMUNE CELL CROSSTALK TO GOVERN
INFLAMMATION AND REPAIR DURING ACUTE AND CHRONIC
LIVER INJURY
In this Research Topic, Weston et al. provide a comprehensive overview regarding the role for
myeloid-derived cells during acute and chronic hepatic injury. More specifically, they describe how
tissue-resident Kupffer cells, infiltrating monocytes/macrophages, dendritic cells, and neutrophils
act in concert to initiate an inflammatory response but also to regenerate tissue following injury.
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Finally, they touch upon the idea that strategies targeting liver
macrophages would require precision medicine to specifically
target pathogenic subsets only.
OUTLINING THE EXTENT OF INNATE
IMMUNE DEFECTS DURING CIRRHOSIS
DEVELOPMENT AND
ACUTE-ON-CHRONIC LIVER FAILURE
Patients with acute decompensated cirrhosis and acute-on-
chronic liver failure (ACLF), display evidence of hepatic
and systemic inflammation but paradoxically also features
of immunosuppression, rendering them highly susceptible to
infections. Within this Research Topic, a clinical investigation by
Trebicka et al. demonstrated that the extent of systemic immune
inflammation in acute decompensated cirrhotics correlates with
a higher risk of disease progression toward ACLF or death of
the patient. Another study by Alvarez-Silva et al. demonstrated
that the levels of inflammatory cytokines and microbial richness
are significantly higher in ascites fluid compared to plasma
samples from patients with decompensated cirrhosis. However,
the authors could not find any correlation between the bacterial
DNA abundance and/or richness and the extent of systemic
inflammation in these patients.
Providing some insight into the molecular mechanisms,
Irvine et al. and Martin-Mateos et al. review the respective innate
immune dysfuntions observed in cirrhosis and ACLF, within this
Research Topic. Furthermore, Irvine et al. propose mechanisms
that improve susceptibility to infections, while Martin-Mateos
et al. highlights mechanisms targeting the gut, -high-grade
systemic inflammation and reverting immune paralysis as
therapeutic opportunities to improve clinical outcome of these
patients. Also within this Research Topic, Triantafyllou et al.
provide an overview of the role of monocytes/macrophages in
driving systemic immunosuppression and hepatic inflammation
thereby contributing to the pathophysiology of acute
decompensated cirrhosis as well as ACLF. Additionally the
authors describe the opportunities and challenges of therapeutic
strategies aiming at reverting Kupffer cell activation, hampering
monocyte recruitment to the liver or manipulating macrophage
polarization to interfere in disease progression. Along the same
line of investigation, Riva and Mehta provide evidence for
epigenetic mechanisms, and the role of checkpoint receptors
in regulating monocyte function. In combination with recent
advances in the field whereby metabolic rewiring can influence
immunological functions (7), these studies open up new
opportunities of targetable pathways that may be exploited to
improve monocyte function in ACLF.
Finally, Moreau et al. placed the spotlight on dysfunctional
neutrophils during cirrhosis within the Research Topic.
More particularly, they provide an overview of defects in
intracellular signaling pathways, impaired activation of the
NADPH oxidase complex, myeloperoxidase (MPO) release
and defective bactericidal activity within neutrophils during
cirrhosis. Importantly, they report some studies that suggest that
defective neutrophil functions, at least in vitro, could be rescued
by TLR7/8 agonists.
TAKING THE BREAK OFF MONOCYTES,
DRIVES INFLAMMATION, AND
INTESTINAL BARRIER BREACH
Patients with advanced stages of cirrhosis often exhibit a
dysfunctional intestinal barrier, whereby luminal bacteria and
their products translocate into the circulation and reach
the liver via the portal vein (gut-liver axis). Very exciting
recent research elucidate for the first time the mechanisms
of intestinal barrier breach during cirrhosis (8). Nevertheless,
how exactly monocytes/macrophages contribute to intestinal
barrier dysfunction remains incompletely understood. Although
not directly linked to an experimental liver disease model, an
interesting study by Mouhadeb et al., may shed some light on
this aspect by demonstrating that disruption of COMMD10, a
protein with yet unknown function, unleashes the inflammatory
capacity of circulating Ly6Chi monocytes, resulting in intestinal
barrier dysfunction and elevated bacterial translocation to the
mouse liver. It would be intriguing to verify whether similar
mechanisms set the stage for pathogenic bacterial translocation
during cirrhosis development.
TARGETING MACROPHAGES DURING
NON-ALCOHOLIC FATTY LIVER DISEASE
Non-alcoholic fatty liver disease (NAFLD) is hallmarked by
chronic low-grade inflammation and lipid accumulation in the
liver as well as in extra-hepatic sites such as adipose tissue.
Furthermore, a complex inter-organ crosstalk fuels the onset and
progression of hepatic injury and fibrosis development. Within
this disease setting, it is well-established that myeloid-derived
cells play a prominent role in regulating inflammation and
metabolism. In this Research Topic, Hundertmark et al. provide
a comprehensive overview of the functional and phenotypic
versatility of myeloid cells as well as the microenvironmental
signals that trigger their activation during NAFLD progression.
Additionally, they point out the existence of an orchestrated
interplay between myeloid cells in different compartments, such
as circulation, gut, adipose tissue, and the liver. Extending along
the same line of investigation, Vonghia et al. review current data
on experimental NAFLD treatment strategies whereby myeloid-
derived cells constitute the targeted population.
In another manuscript within this Research Topic, Liao et al.
demonstrated that palmitate-induced hepatocyte stress resulted
in the release of extracellular vesicles enriched in the lipotoxic
molecule, sphingosine 1-phosphate (S1P). These extracellular
vesicles promoted macrophage chemotaxis through interaction
with the S1P1 receptor on the surface of the macrophages.
Although awaiting further in vivo confirmation, the authors
suggest this to be a novel signaling axis for macrophage
recruitment during NAFLD, where hepatic lipotoxicity prevails.
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MACROPHAGES GOING OFF TRACK IN
THE AGING LIVER
The process of aging is closely associated with a number of
degenerative modifications in the liver, where hepatic structure
and cell function tend to decline. In this Research Topic, Stahl
et al. review macrophage deficits in mitochondrial function,—
decline in autophagy and altered proinflammatory function, are
discussed as possible mechanisms that may be relevant during
age-related liver diseases.
NEUTROPHILS FUELING LIVER ISCHEMIA
AND REPERFUSION INJURY
Hepatic ischemia/reperfusion (I/R) is an important cause
of liver damage occurring during hepatic resection and
liver transplantation. Neutrophils have been shown to be
one of the cellular players contributing towards tissue
injury, however the molecular mechanisms involved have
not been completely defined. Within this Research Topic,
Sun et al. implicate that MAPK-activated protein kinase 2
(MK2) contribute to hepatic I/R since its ablation protects
against hepatic I/R injury in a murine model. This result
implicates MK2 as a potential novel therapeutic target for
I/R injury.
CONCLUSIONS
Emerging evidence demonstrated that myeloid-derived cells
play a key role in the initiation, and progression of liver
disease. This Research Topic provides multiple examples of how
different myeloid cell subsets but also neutrophils can contribute
to the inflammatory processes that underlie the clinical
manifestations of various liver diseases. Such a compilation of
relevant information may uncover new therapeutic targets and
ultimately lead to improved outcomes in patients with advanced
liver disease.
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